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Background: Craniotomy patients have a high incidence of postoperative nausea and vomiting (PONV). This
prospective, randomized, double-blind, multi-center study was performed to evaluate the efficacy of prophylactic
ramosetron in preventing PONV compared with ondansetron after elective craniotomy in adult patients.
Methods: A total of 160 American Society of Anesthesiologists physical status I–II patients aged 19–65 years who were
scheduled to undergo elective craniotomy for various intracranial lesions were enrolled in this study. All patients
received total intravenous anesthesia (TIVA) with propofol and remifentanil. Patients were randomly allocated into
three groups to receive ondansetron (4 mg; group A, n = 55), ondansetron (8 mg; group B, n = 54), or ramosetron
(0.3 mg; group C, n = 51) intravenously at the time of dural closure. The incidence of PONV, the need for rescue
antiemetics, pain score, patient-controlled analgesia (PCA) consumption, and adverse events were recorded 48 h
postoperatively.
Results: Among the initial 160 patients, 127 completed the study and were included in the final analysis. The incidences
of PONV were lower (nausea, 14% vs. 59% and 41%, respectively; P < 0.001; vomiting, P = 0.048) and the
incidence of complete response was higher (83% vs. 37% and 59%, respectively; P < 0.001) in group C than in
groups A and B at 48 h postoperatively. There were no significant differences in the incidence of PONV or need
for rescue antiemetics 0–2 h postoperatively, but significant differences were observed in the incidence of PONV
and complete response among the three groups 2–48 h postoperatively. No statistically significant intergroup
differences were observed in postoperative pain, PCA consumption, or adverse events.
Conclusion: Intravenous administration of ramosetron at 0.3 mg reduced the incidence of PONV and rescue
antiemetic requirement in craniotomy patients. Ramosetron at 0.3 mg was more effective than ondansetron at 4
or 8 mg for preventing PONV in adult craniotomy patients.
Trial registration: Clinical Research Information Service (CRiS) Identifier: KCT0000320. Registered 9 January 2012.
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Postoperative nausea and vomiting (PONV) is one of
the most common perioperative concerns, with a rela-
tively high incidence of up to 73% after craniotomy
[1-5]. PONV usually leads to patient discomfort, delayed
discharge from the intensive care unit (ICU) or hospital,
and increased medical costs [6]. Moreover, severe vomit-
ing may result in dehydration, electrolyte imbalance, and
acid–base disturbance [6].
Neurosurgical patients with PONV are at an increased
risk of aspiration, intracranial or cerebral hypertension,
hematoma formation, and neurological deterioration [7].
After craniotomy, PONV occurs with incidences up to
60% for emesis, and 70% for nausea when no prophylac-
tic antiemetic is administered [8]. The etiology of PONV
in patients undergoing craniotomy is probably multifac-
torial, and well-known risk factors of PONV include age,
gender, a history of motion sickness, and previous
PONV [9]. The effects of neurosurgical risk factors such
as side and site of lesion, presence of midline shift and
mass effect, and tumor pathology on PONV were evalu-
ated, but no significant correlations were observed
[3,10]. Fabling et al. [11] reported that PONV occurred
frequently during the initial 48 h after craniotomy.
Various antiemetics, including anticholinergics and dopa-
mine receptor antagonists, have been studied with re-
gard to their efficacy for the prevention and treatment
of PONV [1,5,12]. However, these agents have been re-
ported to have adverse effects such as excessive sedation,
hypotension, dysphoria, hallucinations, and extrapyramidal
signs [1,5,12,13], all of which are undesirable for neuro-
logical assessment after neurosurgical operations. Selective
5-HT3 receptor antagonists (ondansetron, granisetron, and
tropisetron) are effective in PONV after craniotomy with-
out neurological adverse effects [1,3-5,7,11,14-17]. Ramose-
tron, a selective 5-HT3 receptor antagonist, has been used
effectively in various surgical procedures for the prevention
or treatment of PONV [18]. However, limited data are
available regarding the efficacy of ramosetron for the pre-
vention of PONV in neurosurgical patients and it was sug-
gested that prophylactic administration of ramosetron may
reduce the incidence of PONV after craniotomy compared
with ondansetron. This prospective, randomized, double-
blind, multi-center study was designed to evaluate the effi-
cacy and safety profile of prophylactic administration of




The present study was performed at Seoul National
University Hospital, Seoul National University Bundang
Hospital, Severance Hospital, and Ewha Womans University
Medical Center. The protocol was approved by the EthicsCommittees of each of the above hospitals and regis-
tered in the Clinical Research Information Service
(CRiS, KCT0000320). After obtaining written and in-
formed consent, 160 adult patients (American Society
of Anesthesiologists [ASA] physical status I or II, aged
19–65 years) undergoing elective craniotomy from
January 2012 until March 2013 were included.
Exclusion criteria were gastric disease, pregnancy, a his-
tory of craniotomy, anticancer chemotherapy, antiemetic
use within 24 h, severe renal (serum creatinine > 1.6 mg/dl)
or hepatic insufficiency (liver enzymes more than twice the
normal value), borderline QTc prolongation (>430 msec
for males, > 450 msec for females) on electrocardiography,
chronic use of opioids for more than 2 weeks, antidepres-
sant medication, having undergone an emergency oper-
ation, or those who could not understand the numerical
rating scale (NRS) or communicate (scheduled to be se-
dated postoperatively).
Anesthesia
Anesthesia and monitoring were standardized for all pa-
tients. Patients received no preanesthetic medication.
Standard monitoring included electrocardiography, pulse
oximetry, and noninvasive blood pressure (NIBP) moni-
toring. Induction of anesthesia consisted of propofol
(4 μg/ml) and remifentanil (3–4 ng/ml) using target con-
trolled infusion (TCI). Neuromuscular blockade was per-
formed using intravenous rocuronium 0.6 mg/kg to
facilitate tracheal intubation. During anesthetic induction,
a 20-gauge arterial catheter was inserted into a radial ar-
tery for continuous blood pressure (BP) monitoring or
arterial blood sampling, and the subclavian vein was cath-
eterized using a real-time ultrasound device to monitor
central venous pressures. Propofol (2–4 μg/ml) and remi-
fentanil (2–4 ng/ml) in oxygen and medical air (FiO2 0.5)
were used during maintenance of anesthesia. Ventilation
was mechanically controlled to achieve end-tidal CO2 be-
tween 30 and 35 mmHg. Muscle relaxants were used as
needed to maintain a single twitch on train-of-four stimu-
lation. For intraoperative neurophysiological monitoring,
no additional neuromuscular blocker was administered
during surgery. Temperature was monitored using an
esophageal stethoscope with thermistor and maintained at
36 ± 1°C with a warm pad throughout surgery. At the end
of the surgery, an intravenous patient-controlled analgesia
(PCA) device was connected; the PCA consisted of fen-
tanyl 15 μg/ml (total, 100 ml) and was programmed to
run with a 1-ml bolus dose and 10 min lockout time.
Randomization and intervention
Before induction of anesthesia, the anesthesiologist re-
sponsible for patient allocation randomized the patients
using a computer-generated random number table (Ran-
dom Allocation Software Version 1.0) with block size 3.
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lopes. Patients were allocated randomly to one of three
groups to receive 4 mg of ondansetron (group A), 8 mg
ondansetron (group B), or 0.3 mg ramosetron (group C)
intravenously. Identical 5-ml syringes containing the
same volume (mixed with normal saline to the total vol-
ume of 4 ml) of ondansetron or ramosetron were pre-
pared and administered at the end of surgery (dura
mater closure) by blinded nurses to the group allocation.
Outcomes
After the operation, the patients were transferred to the
intensive care unit (ICU). All patients were observed for
48 h postoperatively. Every episode of nausea or vomit-
ing was recorded under three assessment time frames,
0–2 h, 2–24 h, and 24–48 h, by a blinded nurse. Nausea
was defined as a subjectively unpleasant sensation asso-
ciated with the awareness of the urge to vomit; retching
was defined as labored, spasmodic, rhythmic contraction
of the respiratory muscles without expulsion of gastric
contents; vomiting was defined as the forceful expulsion
of gastric contents from the mouth [4,13]. Complete re-
sponse was regarded as no PONV. The severity of nausea
(NRS with 0 = none to 100 =most severe) was evaluated
verbally to guide the use of rescue antiemetics and, there-
fore, is not presented as a result. The rescue antiemetic
used was 10-mg metoclopramide administered intraven-
ously. This was given to patients whose NRS for nausea
was greater than 30 and for patients who experienced more
than one episode of vomiting or wanted to be treated.
Postoperative pain scores (using NRS with 0 = none to
100 =most severe) and consumption of PCA were also
assessed. All adverse events were reviewed and judged
by the investigator, and the details of clinically significant
adverse events were supposed to be submitted to the
Ethics Committees. Other postoperative adverse events,
such as drowsiness, dizziness, and QTc prolongation,
were also recorded.
Statistical analysis
In the previous study of Kathirvel et al., [3] the inci-
dence of PONV 24 h postoperatively was 44% in pa-
tients with administration of ondansetron 4 mg after
craniotomy. A reduction of 30% in PONV with ramose-
tron was considered clinically significant. The analysis
showed that 46 patients per group would be sufficient to
detect the antiemetic effect of ramosetron (α = 0.0175 and
β = 0.2). We chose 55 patients per group assuming a 20%
drop-out rate.
Continuous variables (age, height, weight, duration of
surgery and anesthesia, pain score, and PCA consump-
tion) were analyzed by ANOVA, and categorical vari-
ables (gender, ASA physical class, type of operation,
preoperative dexamethasone, incidence of PONV andcomplete response, rescue analgesics, and adverse events)
were compared using the chi-squared test or Fisher’s exact
test. Post hoc comparisons were made with Student New-
man Keuls test. Data are expressed as means ± standard
deviation (SD) or counts (%). A p value less than 0.05 was
deemed to indicate statistical significance.
Results
A total of 160 patients from four hospitals were enrolled
in the present study, and 33 were excluded during allo-
cation or the follow-up period. Ultimately, a total of 127
patients completed the study (Figure 1). Twenty-one pa-
tients were chosen to be sedated to protect their brains
intra-operatively or postoperatively, and other patients
were excluded due to perioperative massive bleeding
(n = 3), lack of a postoperative patient visit (n = 2),
minor protocol violations (n = 6; errors in the PCA
regimen and incorrect rescue antiemetics), and patient
refusal (Figure 1). These violations did not impact sub-
ject safety and were considered minor. Patient charac-
teristics and information on surgery and anesthesia are
summarized in Table 1, and there were no statistically
significant differences among the three groups with re-
spect to patient demographic data.
The results for the 0- to 48-h study period suggested
that the incidence of nausea (P < 0.001) and the need for
rescue antiemetics (P = 0.008) were lower in group C
than in groups A or B (Table 2). Additionally, the inci-
dence of complete response (P < 0.001) was significantly
higher in group C than in groups A and B (Table 2).
However, statistically significant differences in the inci-
dence of PONV or complete response were not observed
between A and B groups throughout the study period.
There were no significant differences in the incidence
of PONV and the need for rescue antiemetics 0–2 h
postoperatively. However, significant differences were
observed in the incidence of PONV and complete re-
sponse among the three groups 2–48 h postoperatively
(Table 2). Nausea occurred less frequently and the rate
of complete response was higher in group C than in
group A or B 2–24 and 24–48 h postoperatively
(Table 2). Additionally, rescue antiemetics were less fre-
quently required in group C than in groups A or B 2–
48 h postoperatively (Table 2).
Total incidences of PONV for subgroups that did or
did not receive dexamethasone were analyzed (Table 3).
The incidence of nausea was lower and that of complete
response was higher in group C than group A in both
patients with or without steroid (Table 3).
No significant inter-group difference was observed in
terms of postoperative pain or PCA consumption (Table 4).
Common adverse events related to ramosetron treatment
are headache, dizziness, and drowsiness. In the present
study, headache was not checked because craniotomy
Figure 1 Flow diagram of the patients.
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cluding drowsiness and dizziness, did not reach statistical
significance among the groups (Table 4). There were no
serious adverse events, such as QTc prolongation of elec-
trocardiography or withdrawal of the study drugs.Discussion
The present study was designed to evaluate the anti-
emetic efficacy of ramosetron in adult patients undergo-
ing elective craniotomy. The overall incidence rates of
PONV during the first 48 h after surgery were 63%, 41%,
Table 1 Patients and surgery characteristics
Group A (n = 41) Group B (n = 44) Group C (n = 42) P value
Age (yr) 49 (21–65) 48 (27–65) 53 (23–64) 0.677
Weight (kg) 62 ± 11 62 ± 11 63 ± 11 0.894
Height (cm) 162 ± 8 163 ± 8 163 ± 9 0.728
Gender (M/F) 14/27 19/25 13/29 0.471
Preoperative dexamethasone 17 (41) 15 (34) 11 (26) 0.339
Operation time (min) 249 ± 87 288 ± 117 254 ± 110 0.179
Anesthesia time (min) 321 ± 90 368 ± 131 327 ± 114 0.110
Type of surgery 0.322
Tumor surgery 26 (63) 26 (59) 20 (48)
Vascular surgery 15 (37) 18 (41) 22 (52)
ASA class I/II 24 (59)/17 (41) 22 (50)/22 (50) 22 (52)/20 (48) 0.720
Preexisting disease, (n)
Hypertension 11 13 13 0.916
Diabetes mellitus 4 5 7 0.609
Liver disease 3 2 0 0.223
Group A; ondansetron 4 mg group. Group B; ondansetron 8 mg group. Group C; ramosetron 0.3 mg group. Values are expressed as mean (SD) or number of the
patients (n) except age (mean, range).
Table 2 Incidences of PONV and rescue antiemetics
Group A (n = 41) Group B (n = 44) Group C (n = 42) P value
Postoperative 0–48 h
Nausea 24 (59) 18 (41) 6 (14) † ‡ < 0.001
Retching & Vomiting 9 (22) 9 (20) 3 (7) 0.13
Complete response 15 (37) 26 (59) 35 (83) † < 0.001
Rescue antiemetic 11 (27) 9 (20) 1 (2) † ‡ 0.008
Postoperative 0–2 h
Nausea 6 (15) 5 (11) 2 (5) 0.318
Retching & Vomiting 1 (2) 1 (2) 1 (5) 0.999
Complete response 34 (83) 40 (91) 40 (95) 0.172
Rescue antiemetic 2 (5) 3 (7) 0 (0) 0.249
Postoperative 2–24 h
Nausea 17 (41) 12 (27) 3 (7) † ‡ 0.001
Retching & Vomiting 6 (15) 8 (18) 2 (2) 0.154
Complete response 23 (56) 33 (75) 38 (86) † 0.002
Rescue antiemetic 8 (20) 5 (11) 1 (2) † 0.045
Postoperative 24–48 h
Nausea 16 (39) 14 (32) 4 (10) † 0.006
Retching & Vomiting 4 (10) 5 (11) 0 (0) 0.088
Complete response 25 (61) 30 (68) 38 (90) † 0.006
Rescue antiemetic 5 (12) 6 (14) 0 (0) 0.050
Group A; ondansetron 4 mg group. Group B; ondansetron 8 mg group. Group C; ramosetron 0.3 mg group. Values are expressed as number of the patients (%). †:
<0.0175 compared with Group A. ‡: 0.0175 compared with Group B.
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Table 3 Incidences of PONV and rescue analgesic in patients with or without steroid
Patients without steroid Group A (n = 17) Group B (n = 15) Group C (n = 11) P value
Nausea 10 (21) 6 (40) 0 (0)† 0.007
Retching & Vomiting 3 (17) 1 (7) 0 (0) 0.265
Complete response 7 (41) 9 (60) 11 (100)† 0.007
Rescue antiemetic 4 (24) 2 (13) 0 (0) 0.214
Patients without steroid Group A (n = 24) Group B (n = 29) Group C (n = 31) P value
Nausea 14 (58) 12 (41) 6 (19)† 0.012
Retching & Vomiting 6 (25) 8 (27) 3 (10) 0.178
Complete response 9 (37) 17 (58) 24 (77)† 0.011
Rescue antiemetic 7 (29) 7 (24) 1 (3)† 0.025
Group A; ondansetron 4 mg group. Group B; ondansetron 8 mg group. Group C; ramosetron 0.3 mg group.
Values are expressed as number of the patients (%). †: < 0.0175 compared with Group A.
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ramosetron 0.3 mg groups, respectively. There was no pla-
cebo group in this study because high incidences of
PONV after craniotomy were reported in previous investi-
gations [1,3,4]. Administration of ramosetron 0.3 mg at
the time of dural closure significantly reduced the inci-
dence of PONV and the requirement of rescue antiemetics
compared with ondansetron 4 mg or 8 mg 48 h postoper-
atively without significant adverse events.
Ondansetron, one of the most common 5-HT3 recep-
tor antagonists, has been investigated for the prevention
of PONV after craniotomy, and discrepant results have
been reported regarding the effectiveness of ondansetron
in neurosurgical patients [1,11,14,15,17,19,20]. Con-
versely, previous studies have indicated that the proper
timing of ondansetron administration is at the time of
dural closure for the prevention of PONV in neurosurgi-
cal patients [3,11,17]. Fabling et al. [11] recommendedTable 4 Postoperative pain, recovery profiles and postoperat
Group A (n = 41) G
Postoperative 0–2 h
Pain (VRS) 36 (0–80)
PCA consumption (ml) 1.5 (0–7)
Postoperative 2–24 h
Pain (VRS) 27 (0–100)
PCA consumption (ml) 11 (0–46)
Postoperative 24–48 h
Pain (VRS) 17 (0–80)






Group A; ondansetron 4 mg group. Group B; ondansetron 8 mg group. Group C; ra
the patients (%).ondansetron 8 mg for the prevention of PONV in high-
risk neurosurgical patients. In the present study, the in-
cidences of PONV after prevention with ondansetron 4
and 8 mg were 63 and 41%, respectively.
Ramosetron, another selective 5-HT3 receptor antag-
onist, has been reported to be effective for the preven-
tion and treatment of PONV after various surgeries
[21-27]. Previous investigations have shown that ramose-
tron 0.3 mg was more effective than ondansetron 4 mg in
patients with spine surgery, total knee arthroplasty, and
laparoscopic cholecystectomy [22,24,27] and as effective
as ondansetron 8 mg in patients with gynecological sur-
gery and laparoscopic surgery [25,27]. However, no data
have been reported concerning the antiemetic efficacy of
ramosetron for preventing PONV after craniotomy. It is
noteworthy that ramosetron 0.3 mg was more effective
than ondansetron 8 mg after craniotomy in the present
study. This may have been because the incidence andive adverse effects
roup B (n = 44) Group C (n = 42) P value
41 (0–90) 39 (0–100) 0.974
1.5 (0–8) 1.5 (0–5) 0.921
26 (0–85) 26 (0–70) 0.792
12 (20–75) 13 (0–78) 0.541
15 (0–60) 18(0–70) 0.589
26 (0.2-100) 22 (0–88) 0.345
5 (11) 2 (5) 0.528
14 (32) 6 (14) 0.101
1 (2) 0 (0) 0.604
0 (0) 0 (0) 0.347
mosetron 0.3 mg group. Values are expressed as median (range) or number of
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other surgeries.
Several factors should be taken into consideration dur-
ing investigations of PONV in patients with craniotomy.
PONV in neurosurgical patients is affected by postcra-
niotomy pain and PCA consumption [4]. In the current
study, there were no statistically significant differences
in postcraniotomy pain and PCA consumption among
the groups, and these factors may be considered to have
minimal effect on the results. Additionally, instead of in-
halation agents, total intravenous anesthesia with propofol
and remifentanil was used for maintenance of anesthesia
to monitor the evoked potential and reduce PONV. The
most frequent adverse event following administration of
the selective 5-HT3 receptor antagonist is headache.
Headache was not recorded because it is difficult to dis-
criminate headache from postcraniotomy pain in patients
with neurosurgery.
These phenomena could be explained by the potency
of the two drugs. The results of previous meta-analyses
showed that ramosetron was effective for preventing
PONV without adverse effects and also had statistically
significant differences for prevention of early and late
PONV compared with ondansetron [18,28]. However,
ramosetron (about US $23 for 0.3 mg) is more expensive
than ondansetron (US $5 for 4 mg and US $8 for 8 mg)
in Korea. The choice and use of antiemetics should be
individualized considering cost effective benefits.
The present study had a few limitations. First, the
study population consisted of patients with various intra-
cranial diseases, including tumors and vascular lesions.
Additionally, patients with intracranial tumors may be
using preoperative dexamethasone to reduce cerebral
edema. Dexamethasone, a corticosteroid, has effective
antiemetic action and reduces the degree and incidence
of PONV [29], although few studies have investigated
the effects of preoperative steroid use on the incidence
of PONV in neurosurgical patients. In the present study,
no significant differences were found in the number of
patients with preoperative steroid use among the three
groups, a finding that may cause some (but minimal)
confusion in the interpretation of the results. Second,
the incidences of PONV in patients with craniotomy
were reported to be high, and combined antiemetic mea-
sures with different sites of action are recommended for
this high-risk group [9]. The aim of the present study
was to evaluate the efficacy of ramosetron alone for the
prevention of PONV in neurosurgical patients, and fur-
ther studies of combination antiemetics for neurosurgical
patients are needed. Third, the sample size calculation
was based on the previous investigation of Kathirvel et al.
and the incidence of PONV was 44% [3]. However, all
patients of Kathirvel’s investigation received dexa-
methasone for 24 hours whereas 34% of the patients inthis study were administered preoperative dexametha-
sone. In addition, anesthesia was maintained with N2O
and isoflurane in the previous study of Kathirvel et al.
[3] instead of TIVA using propofol-remifentanil of the
present study. These factors may have influenced on
the incidence of PONV. Forth, minimal calculated sam-
ple size estimated to detect the difference in the pri-
mary outcome among the three study groups (46
patients per group) was not finally achieved because
more patients than we expected have been dropped out
during study period of the 4 centers. This may influ-
ence the statistical significance in that the lack of differ-
ence between the two ondansetron groups could be
related to inadequate sample size.
Conclusion
Intravenous administration of ramosetron 0.3 mg at the
end of surgery was more effective than ondansetron 4 or
8 mg for the prevention of PONV in patients undergoing
elective craniotomy under total intravenous anesthesia
using propofol and remifentanil. Future studies of multi-
modal prophylactic strategies with ramosetron and other
antiemetics in this high-risk patient population are needed.
Abbreviations
BP: Blood pressure; ICU: Intensive care unit; NIBP: Noninvasive blood
pressure; NRS: Numerical rating scale; PCA: Patient-controlled analgesia;
PONV: Postoperative nausea and vomiting; TCI: Target controlled infusion;
TIVA: Total intravenous anesthesia.
Competing interests
The authors have no conflicts of interest or financial ties to disclose.
Authors’ contributions
JHR, YJL, HJP, KTM and SHD contributed study design. JEL, DMH, HPP, JIH,
and HZK collected and analyzed data. JHR and SHD drafted the manuscript.
JHR, HJB and KTM made critical revisions of the manuscript. All authors read
and approved the final analysis of the manuscript.
Acknowledgements
The authors thank MRCC (medical research cooperation center) of Seoul
National University Bundang Hospital for their statistical assistance.
Author details
1Department of Anesthesiology and Pain Medicine, Seoul National University
Bundang Hospital, 166 Gumi-ro, Bundang-gu, Seongnam-si, Gyeonggi-do
463-707, South Korea. 2Department of Anesthesiology and Pain Medicine,
Seoul National University Hospital, Seoul, South Korea. 3Department of
Anesthesiology and Pain Medicine, College of Medicine, Seoul National
University, Seoul, South Korea. 4Department of Anesthesiology and Pain
Medicine, School of Medicine, Ewha Womans University, Seoul, Korea.
5Department of Anesthesiology and Pain Medicine, Severance Hospital,
Seoul, South Korea.
Received: 21 March 2014 Accepted: 28 July 2014
Published: 4 August 2014
References
1. Fabling JM, Gan TJ, El-Moalem HE, Warner DS, Borel CO: A randomized,
double-blinded comparison of ondansetron, droperidol, and placebo for
prevention of postoperative nausea and vomiting after supratentorial
craniotomy. Anesth Analg 2000, 91(2):358–361.
Ryu et al. BMC Anesthesiology 2014, 14:63 Page 8 of 8
http://www.biomedcentral.com/1471-2253/14/632. Fabling JM, Gan TJ, Guy J, Borel CO, El-Moalem HE, Warner DS: Postoperative
nausea and vomiting. A retrospective analysis in patients undergoing
elective craniotomy. J Neurosurg Anesthesiol 1997, 9(4):308–312.
3. Kathirvel S, Dash HH, Bhatia A, Subramaniam B, Prakash A, Shenoy S: Effect
of prophylactic ondansetron on postoperative nausea and vomiting
after elective craniotomy. J Neurosurg Anesthesiol 2001, 13(3):207–212.
4. Madenoglu H, Yildiz K, Dogru K, Kurtsoy A, Guler G, Boyaci A: Randomized,
double-blinded comparison of tropisetron and placebo for prevention of
postoperative nausea and vomiting after supratentorial craniotomy.
J Neurosurg Anesthesiol 2003, 15(2):82–86.
5. Pugh SC, Jones NC, Barsoum LZ: A comparison of prophylactic
ondansetron and metoclopramide administration in patients undergoing
major neurosurgical procedures. Anaesthesia 1996, 51(12):1162–1164.
6. Kovac AL: Prevention and treatment of postoperative nausea and
vomiting. Drugs 2000, 59(2):213–243.
7. Neufeld SM, Newburn-Cook CV: The efficacy of 5-HT3 receptor antagonists
for the prevention of postoperative nausea and vomiting after craniotomy:
a meta-analysis. J Neurosurg Anesthesiol 2007, 19(1):10–17.
8. Eberhart LH, Morin AM, Kranke P, Missaghi NB, Durieux ME, Himmelseher S:
Prevention and control of postoperative nausea and vomiting in post-
craniotomy patients. Best Pract Res Clin Anaesthesiol 2007, 21(4):575–593.
9. Gan TJ, Meyer T, Apfel CC, Chung F, Davis PJ, Eubanks S, Kovac A, Philip BK,
Sessler DI, Temo J, Gan TJ, Meyer T, Apfel CC, Chung F, Davis PJ, Eubanks S,
Kovac A, Philip BK, Sessler DI, Temo J, Tramèr MR, Watcha M: Consensus
guidelines for managing postoperative nausea and vomiting. Anesth
Analg 2003, 97(1):62–71. Table of contents.
10. Irefin SA, Schubert A, Bloomfield EL, DeBoer GE, Mascha EJ, Ebrahim ZY: The
effect of craniotomy location on postoperative pain and nausea. J Anesth
2003, 17(4):227–231.
11. Fabling JM, Gan TJ, El-Moalem HE, Warner DS, Borel CO: A randomized,
double-blind comparison of ondansetron versus placebo for prevention
of nausea and vomiting after infratentorial craniotomy. J Neurosurg
Anesthesiol 2002, 14(2):102–107.
12. Meng L, Quinlan JJ: Assessing risk factors for postoperative nausea and
vomiting: a retrospective study in patients undergoing retromastoid
craniectomy with microvascular decompression of cranial nerves.
J Neurosurg Anesthesiol 2006, 18(4):235–239.
13. Watcha MF, White PF: Postoperative nausea and vomiting. Its etiology,
treatment, and prevention. Anesthesiology 1992, 77(1):162–184.
14. Hartsell T, Long D, Kirsch JR: The efficacy of postoperative ondansetron
(Zofran) orally disintegrating tablets for preventing nausea and vomiting
after acoustic neuroma surgery. Anesth Analg 2005, 101(5):1492–1496.
15. Jain V, Mitra JK, Rath GP, Prabhakar H, Bithal PK, Dash HH: A randomized,
double-blinded comparison of ondansetron, granisetron, and placebo
for prevention of postoperative nausea and vomiting after supratentorial
craniotomy. J Neurosurg Anesthesiol 2009, 21(3):226–230.
16. Wang YJ, Cheng ZG, Guo QL: Clinical observation of granisetron in
preventing postoperative nausea and vomiting following supratentorial
craniotomy. Hunan Yi Ke Da Xue Xue Bao 2002, 27(6):545–546.
17. Wig J, Chandrashekharappa KN, Yaddanapudi LN, Nakra D, Mukherjee KK:
Effect of prophylactic ondansetron on postoperative nausea and
vomiting in patients on preoperative steroids undergoing craniotomy
for supratentorial tumors. J Neurosurg Anesthesiol 2007, 19(4):239–242.
18. Kim WO, Koo BN, Kim YK, Kil HK: Ramosetron for the prevention of
postoperative nausea and vomiting (PONV): a meta-analysis. Korean J
Anesthesiol 2011, 61(5):405–412.
19. Habib AS, Keifer JC, Borel CO, White WD, Gan TJ: A comparison of the
combination of aprepitant and dexamethasone versus the combination
of ondansetron and dexamethasone for the prevention of postoperative
nausea and vomiting in patients undergoing craniotomy. Anesth Analg
2011, 112(4):813–818.
20. Sinha PK, Tripathi M, Ambesh SP: Efficacy of ondansetron in prophylaxis of
postoperative nausea and vomiting in patients following infratentorial
surgery: a placebo-controlled prospective double-blind study. J Neurosurg
Anesthesiol 1999, 11(1):6–10.
21. Choi DK, Chin JH, Lee EH, Lim OB, Chung CH, Ro YJ, Choi IC: Prophylactic
control of post-operative nausea and vomiting using ondansetron and
ramosetron after cardiac surgery. Acta Anaesthesiol Scand 2010, 54(8):962–969.
22. Choi YS, Shim JK, Ahn SH, Kwak YL: Efficacy comparison of ramosetron with
ondansetron on preventing nausea and vomiting in high-risk patientsfollowing spine surgery with a single bolus of dexamethasone as an adjunct.
Korean J Anesthesiol 2012, 62(6):543–547.
23. Choi YS, Shim JK, Yoon Do H, Jeon DH, Lee JY, Kwak YL: Effect of
ramosetron on patient-controlled analgesia related nausea and vomiting
after spine surgery in highly susceptible patients: comparison with
ondansetron. Spine (Phila Pa 1976) 2008, 33(17):E602–E606.
24. Hahm TS, Ko JS, Choi SJ, Gwak MS: Comparison of the prophylactic anti-
emetic efficacy of ramosetron and ondansetron in patients at high-risk
for postoperative nausea and vomiting after total knee replacement.
Anaesthesia 2010, 65(5):500–504.
25. Kim SI, Kim SC, Baek YH, Ok SY, Kim SH: Comparison of ramosetron with
ondansetron for prevention of postoperative nausea and vomiting in
patients undergoing gynaecological surgery. Br J Anaesth 2009,
103(4):549–553.
26. Lee JW, Park HJ, Choi J, Park SJ, Kang H, Kim EG: Comparison of
ramosetron’s and ondansetron’s preventive anti-emetic effects in highly
susceptible patients undergoing abdominal hysterectomy. Korean J
Anesthesiol 2011, 61(6):488–492.
27. Ryu J, So YM, Hwang J, Do SH: Ramosetron versus ondansetron for the
prevention of postoperative nausea and vomiting after laparoscopic
cholecystectomy. Surg Endosc 2010, 24(4):812–817.
28. Mihara T, Tojo K, Uchimoto K, Morita S, Goto T: Reevaluation of the
effectiveness of ramosetron for preventing postoperative nausea and
vomiting: a systematic review and meta-analysis. Anesth Analg 2013,
117(2):329–339.
29. De Oliveira GS Jr, Castro-Alves LJ, Ahmad S, Kendall MC, McCarthy RJ:
Dexamethasone to prevent postoperative nausea and vomiting: an
updated meta-analysis of randomized controlled trials. Anesth Analg
2013, 116(1):58–74.
doi:10.1186/1471-2253-14-63
Cite this article as: Ryu et al.: A prospective, randomized, double-blind,
and multicenter trial of prophylactic effects of ramosetron on
postoperative nausea and vomiting (PONV) after craniotomy:
comparison with ondansetron. BMC Anesthesiology 2014 14:63.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
